2022
Support Models for Addiction Related Treatment (SMART) for pregnant women: Study protocol of a cluster randomized trial of two treatment models for opioid use disorder in prenatal clinics
Forray A, Mele A, Byatt N, Tobon A, Gilstad-Hayden K, Hunkle K, Hong S, Lipkind H, Fiellin DA, Callaghan K, Yonkers KA. Support Models for Addiction Related Treatment (SMART) for pregnant women: Study protocol of a cluster randomized trial of two treatment models for opioid use disorder in prenatal clinics. PLOS ONE 2022, 17: e0261751. PMID: 35025898, PMCID: PMC8758001, DOI: 10.1371/journal.pone.0261751.Peer-Reviewed Original ResearchConceptsOpioid use disorderPregnant womenUse disordersPrenatal clinicsClinical trialsReproductive health cliniciansCollaborative care approachTRIAL REGISTRATION NUMBERCommunity Healthcare OutcomesMatched-pair clusterPatient treatment engagementTreatment modelObstetric providersOUD treatmentPrimary outcomeObstetrical providersPostpartum womenHealth cliniciansCare approachRegistration numberTreatment engagementRelated treatmentsHealthcare outcomesTrialsWomen
2017
Progesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study
Forray A, Gilstad-Hayden K, Suppies C, Bogen D, Sofuoglu M, Yonkers KA. Progesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study. Psychoneuroendocrinology 2017, 86: 96-103. PMID: 28926762, PMCID: PMC5659923, DOI: 10.1016/j.psyneuen.2017.09.012.Peer-Reviewed Original ResearchConceptsPre-pregnancy smokingSmoking levelsWeek 8Progesterone levelsPlacebo-controlled pilot trialDouble-blind studyOral micronized progesteroneSerious adverse eventsWeeks of gestationMain outcome measuresHalf of womenEndogenous progesterone levelsRelapse prevention strategiesCurrent pilot studyPreliminary findingsPostpartum smokersMicronized progesteronePlacebo groupProgesterone groupProgesterone replacementEligible womenSecondary outcomesAdverse eventsPoint prevalencePostpartum women
2014
Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study
Yonkers KA, Forray A, Nich C, Carroll KM, Hine C, Merry BC, Shaw H, Shaw J, Sofuoglu M. Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study. The Lancet Psychiatry 2014, 1: 360-367. PMID: 25328863, PMCID: PMC4199242, DOI: 10.1016/s2215-0366(14)70333-5.Peer-Reviewed Original ResearchCocaine use disorderCocaine usePostpartum womenPost trialUse disordersPlacebo-controlled pilot trialOral micronized progesteronePositive urine testPost-partum womenGroup differencesSelf-reported daysMultiple brain functionsUse of cocaineMicronized progesteroneObstetrical clinicTherapeutic breakProgesterone replacementAdverse eventsUS National InstitutesProgesterone treatmentUrine testsPilot trialRate of submissionStudy biostatisticianProgesterone
2013
Antidepressant Use in Pregnant and Postpartum Women
Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant Use in Pregnant and Postpartum Women. Annual Review Of Clinical Psychology 2013, 10: 369-392. PMID: 24313569, PMCID: PMC4138492, DOI: 10.1146/annurev-clinpsy-032813-153626.Peer-Reviewed Original ResearchConceptsAntidepressant usePersistent pulmonary hypertensionAdverse birth outcomesNeonatal complicationsShortened gestationPulmonary hypertensionAntidepressant exposureBirth outcomesPregnant womenPostpartum womenFetal growthMajor teratogensReproductive yearsLate pregnancyNeonatal signsCardiac malformationsAntidepressantsPregnancyAnxiety disordersAdverse effectsInconclusive evidenceWomenInconsistent literatureMalformationsRisk